ICCC
ImmuCell Corporation
NASDAQ: ICCC · HEALTHCARE · BIOTECHNOLOGY
$8.44
+1.08% today
Updated 2026-04-29
Market cap
$74.64M
P/E ratio
—
P/S ratio
2.70x
EPS (TTM)
$-0.12
Dividend yield
—
52W range
$5 – $8
Volume
0.0M
ImmuCell Corporation (ICCC) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-3.76%
Operating margin
9.73%
ROE
-3.81%
ROA
3.49%
Debt/equity
0.46x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $4.80M | $647137.00 | 60.79% | 16.05% | 13.48% |
| 2007 | $6.07M | $662138.00 | 62.62% | 14.37% | 10.91% |
| 2008 | $4.63M | $-468557.00 | 44.77% | -25.20% | -10.11% |
| 2009 | $4.51M | $-216493.00 | 53.25% | -11.69% | -4.80% |
| 2010 | $4.39M | $-384684.00 | 52.49% | -15.74% | -8.77% |
| 2011 | $5.11M | $-409510.00 | 55.05% | -12.38% | -8.01% |
| 2012 | $5.39M | $89512.00 | 56.67% | 4.55% | 1.66% |
| 2013 | $6.01M | $117395.00 | 50.95% | -0.33% | 1.95% |
| 2014 | $7.60M | $-167159.00 | 58.56% | -2.72% | -2.20% |
| 2015 | $10.23M | $1.21M | 61.11% | 20.75% | 11.86% |
| 2016 | $9.54M | $508448.00 | 56.80% | 9.33% | 5.33% |
| 2017 | $10.43M | $-168000.00 | 50.05% | -2.33% | -1.61% |
| 2018 | $10.99M | $-2.32M | 47.28% | -13.17% | -21.14% |
| 2019 | $13.72M | $-1.30M | 49.11% | -6.95% | -9.44% |
| 2020 | $15.34M | $-1.02M | 44.73% | -8.99% | -6.66% |
| 2021 | $19.24M | $-78292.00 | 44.98% | 1.34% | -0.41% |
| 2022 | $18.57M | $-2.49M | 41.19% | -12.38% | -13.43% |
| 2023 | $17.47M | $-5.77M | 25.16% | -32.90% | -33.05% |
| 2024 | $26.49M | $-2.16M | 29.97% | -6.19% | -8.14% |
| 2025 | $27.64M | $-1.04M | 41.40% | 5.97% | -3.76% |